newsfilter
← Latest News
GlobeNewswire·

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein